GILD Gilead Sciences

Q2 2025 10-Q

Filed: Aug 7, 2025Period ending Jun 30, 2025

Health Care

Biological Products, (No Diagnostic Substances)SEC EDGAR

Gilead Sciences (GILD) 10-Q quarterly report for Q2 2025, filed with SEC EDGAR on Aug 7, 2025 for the fiscal period ending Jun 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q2 2025 10-Q

Management Discussion & Analysis

• No quarterly revenue or profitability data disclosed in provided MD&A text
• No segment or product line performance details included

+2 more insights

Risk Factors

• New risk: FDA "boxed warning" on CAR T therapies in Jan 2024 for secondary T-cell malignancies, impacting Yescarta and Tecartus labeling
• Updated regulatory risk: IRA increasing 2023-25 Medicare discounts and rebates, reducing profitability through new Part D payment rules

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$7.1B

▲ +1.8% YoY▲ +6.2% QoQ

Net Income

$2.0B

▲ +21.4% YoY▲ +49.0% QoQ

Operating Margin

34.9%

▼ -309bp YoY▲ +138bp QoQ

Net Margin

27.7%

▲ +447bp YoY▲ +795bp QoQ

EPS (Diluted)

$1.57

▲ +21.7% YoY▲ +51.0% QoQ

Operating Cash Flow

$827M

▼ -37.6% YoY▼ -52.9% QoQ

Source: XBRL data from Gilead Sciences Q2 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Gilead Sciences Quarterly Reports

Q3 2025 10-Q

Q1 2025 10-Q

Get deeper insights on Gilead Sciences

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.